Intravenous immunoglobulin and Alzheimer's disease: what now? (Q27000371)

Journal of Neuroinflammation

language of work or name

1 reference

5 June 2013

4 references

25 April 2019

27 November 2019

13 December 2019

4 references

25 April 2019

27 November 2019

13 December 2019

10

1 reference

page(s)

70

1 reference

Creative Commons Attribution 2.0 Generic

copyright license

3 references

Europe PubMed Central

25 April 2019

Europe PubMed Central

27 November 2019

Europe PubMed Central

on focus list of Wikimedia project

13 December 2019

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Clearance of amyloid-beta by circulating lipoprotein receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Using animal models to determine the significance of complement activation in Alzheimer's disease

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Anti-inflammatory actions of intravenous immunoglobulin

21 March 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

21 March 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

The advantage of specific intravenous immunoglobulin (sIVIG) on regular IVIG: experience of the last decade

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Does vascular pathology contribute to Alzheimer changes?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

2012 Alzheimer's disease facts and figures

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Abeta-directed single-chain antibody delivery via a serotype-1 AAV vector improves learning behavior and pathology in Alzheimer's disease mice

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Identification of a receptor required for the anti-inflammatory activity of IVIG.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Natural human antibodies to amyloid beta peptide

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Differences between IGIV products: impact on clinical outcome

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Anti-inflammatory properties of pro-inflammatory interferon-gamma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Advanced glycation end-products: a review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Acute renal failure after large doses of intravenous immune globulin

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Side-effects of intravenous immune globulins

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Hemolytic anemia following intravenous gamma globulin administration

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Effect of IgG anti-Rho(D) in adult patients with chronic autoimmune thrombocytopenia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Treatment of childhood idiopathic thrombocytopenic purpura with Rhesus antibodies (anti-D).

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Are soluble monocyte-derived HLA class II molecules candidates for immunosuppressive activity?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Activation of the classical complement pathway in brain tissue of Alzheimer patients

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease.

31 May 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-10-70

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-10-70

Intravenous immunoglobulin products contain specific antibodies to recombinant human tau protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-10-70

Vascular risk factors in Alzheimer's disease - preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-10-70

Epidemiology of chronic kidney disease: results from a population of older adults in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-10-70

Call for guidelines for monitoring renal function and haematological variables during intravenous infusion of immunoglobulin in neurological patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-10-70

Neutropenia as a complication of high-dose intravenous immunoglobulin therapy in adult patients with neuroimmunologic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-10-70

Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-10-70

Effect of IVIG administration on complement activation and HLA antibody levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-10-70

Therapeutic activities of intravenous immunoglobulins in multiple sclerosis involve modulation of chemokine expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-10-70

Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-10-70

Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-10-70

RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-10-70

Intravenous immunoglobulins and transforming growth factor beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-10-70

TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-10-70

Specific antibodies to soluble alpha-synuclein conformations in intravenous immunoglobulin preparations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-10-70

Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-10-70

Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-10-70

Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-10-70

Transforming growth factor-beta 1 is in plaques in Alzheimer and Down pathologies.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3720252

Shortage of human intravenous immunoglobulin—reasons and possible solutions

28 November 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-10-70

High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events

21 January 2018

1 reference

12 December 2020

Thrombotic events after intravenous immunoglobulin

1 reference

12 December 2020

Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study

1 reference

12 December 2020

Soluble HLA class I and class II concentrations in commercial immunoglobulin preparations

1 reference

12 December 2020

Variation of anti-Fas antibodies in different lots of intravenous immunoglobulin

1 reference

12 December 2020

Human plasma contains cross-reactive Abeta conformer-specific IgG antibodies

1 reference

12 December 2020

Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations

1 reference

12 December 2020

Comparison of intravenous immunoglobulins for naturally occurring autoantibodies against amyloid-beta

1 reference

12 December 2020

Intravenous immunoglobulins induce CD32-mediated platelet aggregation in vitro

1 reference

12 December 2020

Immunologically active proteins in intravenous immunoglobulin

1 reference

12 December 2020

Antibody concentrations to Abeta1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations

1 reference

12 December 2020

Identifiers

DOI

10.1186/1742-2094-10-70

1 reference